Press Releases

Nov 06, 2018

Jul 10, 2018

ProBioGen and Pionyr Immunotherapeutics Initiate a Second Immuno-Oncology Contract Development and Manufacturing Project

Jun 26, 2018

ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform

May 24, 2018

ProBioGen Announces Further Development Milestone for Use of Its GlymaxX® Cancer Cell-Killing Enhancement Antibody Technology with Merus N.V.

Apr 18, 2018

ProBioGen signs Second Contract Development Agreement with Tizona Therapeutics for Immuno-Oncology Antibody Project

Mar 08, 2018

ProBioGen and Surface Oncology Sign Second Antibody Manufacturing Program

Feb 07, 2018

ProBioGen and TEVA sign License Agreement on Human Artificial Lymph Node Technology

Oct 05, 2017

Chiome Bioscience Selects ProBioGen for GlymaxX® Antibody Manufacturing Program

Jun 15, 2017

ProBioGen grants a license for human lymph node technology to TissUse for Multi-Organ-Chip applications

Jun 01, 2016

Merus N.V. Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology

Page 6 of 11

Press Releases

ProBioGen Announces Successful Bispecific GlymaxX® Development Project for Zymeworks

ProBioGen and Pionyr Immunotherapeutics Initiate a Second Immuno-Oncology Contract Development and Manufacturing Project

ProBioGen and Nouscom Sign License Agreement for ProBioGen’s Technology Platform

ProBioGen Announces Further Development Milestone for Use of Its GlymaxX® Cancer Cell-Killing Enhancement Antibody Technology with Merus N.V.

ProBioGen signs Second Contract Development Agreement with Tizona Therapeutics for Immuno-Oncology Antibody Project

ProBioGen and Surface Oncology Sign Second Antibody Manufacturing Program

ProBioGen and TEVA sign License Agreement on Human Artificial Lymph Node Technology

Chiome Bioscience Selects ProBioGen for GlymaxX® Antibody Manufacturing Program

ProBioGen grants a license for human lymph node technology to TissUse for Multi-Organ-Chip applications

Merus N.V. Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology